Law 360 M&A

AUGUST 4, 2022

Biotechnology company Amgen Inc., led by Wachtell Lipton Rosen & Katz, will purchase Latham & Watkins LLP-steered biopharmaceutical company ChemoCentryx Inc., billion, the companies announced Thursday. for an enterprise value of $3.7

Enterprise Value 40

Enterprise Value 40

Law 360 M&A

JANUARY 31, 2023

biotechnology company Amgen Inc. and Ireland-based drugmaker Horizon Therapeutics PLC revealed in filings with the U.S. Securities and Exchange Commission on Monday that the Federal Trade Commission is reviewing their proposed $28 billion merger.

40

40

Benzinga

AUGUST 4, 2022

Shares of ChemoCentryx, Inc. NASDAQ: CCXI ) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. A ChemoCentryx press release announced that Amgen, Inc. NASDAQ: AMGN ) has acquired the company in an all-cash deal. Why Is It Moving?

Marketability 52

Marketability 52

Law 360 M&A

JANUARY 5, 2023

Biopharmaceutical company Horizon Therapeutics PLC and the members of its board have been hit with a shareholder suit alleging they failed to supply investors with critical information about its proposed $27.8 billion acquisition by Amgen Inc.

40

40

Benzinga

NOVEMBER 30, 2022

Horizon Therapeutics Plc (NASDAQ: HZNP ) confirmed it's engaged in preliminary talks with Amgen Inc (NASDAQ: AMGN ), Janssen Global Service , and Sanofi SA SNY on potential takeover offers for the company. SVB Leerink projects 2023 revenue of $4.0 billion, adj operating income of $1.6 billion, and EPS of $5.51.

52

52

Business Wire M&A

FEBRUARY 24, 2023

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP): RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a newly formed private limited company wholly owned by Amgen Inc.

40

40

Business Wire M&A

JANUARY 27, 2023

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP): RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a newly formed private limited company wholly owned by Amgen Inc.

40

40

Business Wire M&A

JANUARY 23, 2023

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP): RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a newly formed private limited company wholly owned by Amgen Inc.

Comps 40

Comps 40

Benzinga

DECEMBER 13, 2022

When companies start buying each other at a big premium to what the market’s willing to pay, it tells you that stocks entirely, the whole market, may just be too cheap,” Cramer said, according to the report. Here are the deals that Cramer was referring to: Amgen, Inc. What Happened : “Mergers matter.

Enterprise Value 52

Enterprise Value Marketability 52

Business Wire M&A

JANUARY 23, 2023

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (NASDAQ: HZNP): RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a newly formed private limited company wholly owned by Amgen Inc.

40

40

Harvard Corporate Governance

OCTOBER 5, 2022

law based on a company’s climate-related disclosures if the rule is promulgated as proposed, as well as potential defenses to those claims. Indeed, plaintiffs have already brought claims alleging material misrepresentations regarding how companies calculate the financial impact of certain projects with climate change implications.

Marketability 199

Marketability 199

Benzinga

NOVEMBER 16, 2023

-- The combined company will operate as Q32 Bio Inc., 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. -- The combined company will operate as Q32 Bio Inc., and BEDFORD, Mass.,

Finance 45

Finance Technology 45

Reynolds Holding

JANUARY 21, 2024

As we previously discussed, the new Merger Guidelines demonstrate an increased focus on vertical and conglomerate transactions, competition for labor, potential competition, transactions involving private equity and technology companies, and market trends toward concentration. In Louisiana Children’s Medical Center/HCA Healthcare, Inc.

Marketability 45

Marketability Technology Equity 45